Skip to main content
Equibles
SINT logo

SINT · Sintx Technologies, Inc. · Metrics

Track SINT — free

Use SINT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SINT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.16 +0.03 (+1.41%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Despite the actions undertaken by management to improve liquidity and operating costs—including the divestiture of non-core operations, implementation of cost and pricing improvement initiatives, commercialization of newly cleared medical products, access to capital through the Company’s ATM program, and execution of the Armor facility sublease—management has concluded that substantial doubt remains regarding the Company’s ability to continue as a going concern for a period of at least 12 months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$12.53M
Shares
6.66M
Volume · Oct 2 49.22K Avg daily vol (3M) 108.98K

SINT metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.13
Market cap
$12.53M

Price action

20 metrics
Price change (1W)
+13.9%
Price change (30D)
+40.1%
Price change (3M)
+12.1%
Price change (6M)
-15.5%
Price change (YTD)
-44.8%
Price change (1Y)
-47.7%
Trailing year
Price change (5Y)
—
52-week high
$4.52
52-week low
$1.40
Change from 52-week high
-52.9%
Change from 52-week low
+52.1%
Annualized volatility
73.7%
Annualized volatility (3M)
71.1%
Beta
1.7
RSI (14D)
68.3
Price vs SMA 50
+26.4%
Price vs SMA 200
-12.0%
Avg volume (3M)
108,977
Relative volume
6.2
Average dollar volume
$193,818

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
6.66M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.4×
reciprocal yield 10.6%
P / book
2.6
reciprocal yield 38.5%
FCF yield
-82.5%
TTM · current market cap
Buyback yield
1.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-90.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
12.9×
reciprocal yield 7.8%
EV / revenue historical average (5Y)
11.4×
reciprocal yield 8.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-01

Profitability

9 metrics
Gross margin
52.9%
Operating margin
-884.8%
Trailing 12 months
Net margin
-848.2%
Gross profit (TTM)
$703,000
Operating profit (TTM)
−$11.77M
Net income (TTM)
−$11.28M
Trailing 12 months
Diluted EPS (TTM)
$-5.41
FCF margin
-777.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.74

Growth

11 metrics
Revenue growth YoY
+199.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+91.3%
Year over year · more shares
Revenue CAGR (3Y)
-13.3%
Revenue CAGR (5Y)
+11.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-233.6%
Return on assets
-108.2%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$10.34M
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.59M
Total assets
$10.43M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.12M
Capital expenditures (TTM)
$217,000
R&D (TTM)
$3.17M
SG&A (TTM)
—
Stock compensation (TTM)
$2.04M
R&D / revenue
238.3%
Stock compensation / revenue
153.7%

Ownership (13F)

3 metrics
13F filers
20
13F filer change QoQ
-1
Institutional ownership
14.5%

Short interest

3 metrics
Short interest
1.5%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1269026 CUSIP 829392703 13F (30d) 2 filings 2 filers Visit website Investor relations